Cullinan reports $439M cash, $219.9M net loss; CLN-978 data and zipalertinib NDA on track

Cullinan Therapeutics, Inc.

Cash and investments of $439.0M as of Dec 31, 2025; runway into 2029.
Net loss of $50.7M in Q4 2025 ($219.9M full year), vs $47.6M in Q4 2024.
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA in Q3 2026.
Zipalertinib rolling NDA submission completed; REZILIENT3 frontline study enrollment completed, top-line results by year-end 2026.
Cullinan eligible for $30M upon 2L U.S. approval, up to $100M upon 1L, plus 50/50 profit share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.